News & Events
2006 Press Releases
Eidogen-Sertanty Announces Worldwide Technology Licensing Agreement with Pfizer
San Diego, CA (September 20, 2006) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, today announced a worldwide technology licensing agreement with Pfizer Inc, encompassing Eidogen-Sertanty's drug discovery software and database technology.
Under the terms of the agreement, Pfizer will obtain worldwide access to Eidogen-Sertanty's suite of discovery informatics technologies, including the TIP Structural Knowledgebase, EVE Comparative Visualizer, Chemical Intelligence Platform (ChIP), and Activity-Reaction-Knowledge Archival system (ARK). In addition, Pfizer has licensed access to the core algorithms of TIP, including STRUCTFAST, SiteSeeker, StructSorter, and SiteSorter.
"We are very excited about our ongoing alliance with Pfizer. The deal represents an expansion of Eidogen-Sertanty's relationship with Pfizer, which began in early 2005," said Steve Muskal, CEO of Eidogen-Sertanty. "Our relationship and global licensing arrangement with the world's largest pharmaceutical company demonstrate our products' significant role in drug discovery research."
For more information, please contact:
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.